APA

Komatsu S., Nomiyama T., Numata T., Kawanami T., Hamaguchi Y., Iwaya C., Horikawa T., Fujimura-Tanaka Y., Hamanoue N., Motonaga R., Tanabe M., Inoue R., Yanase T. & Kawanami D. (20201119). SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. : Endocrine journal.

Chicago

Komatsu Shiho, Nomiyama Takashi, Numata Tomohiro, Kawanami Takako, Hamaguchi Yuriko, Iwaya Chikayo, Horikawa Tsuyoshi, Fujimura-Tanaka Yuki, Hamanoue Nobuya, Motonaga Ryoko, Tanabe Makito, Inoue Ryuji, Yanase Toshihiko and Kawanami Daiji. 20201119. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. : Endocrine journal.

Harvard

Komatsu S., Nomiyama T., Numata T., Kawanami T., Hamaguchi Y., Iwaya C., Horikawa T., Fujimura-Tanaka Y., Hamanoue N., Motonaga R., Tanabe M., Inoue R., Yanase T. and Kawanami D. (20201119). SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. : Endocrine journal.

MLA

Komatsu Shiho, Nomiyama Takashi, Numata Tomohiro, Kawanami Takako, Hamaguchi Yuriko, Iwaya Chikayo, Horikawa Tsuyoshi, Fujimura-Tanaka Yuki, Hamanoue Nobuya, Motonaga Ryoko, Tanabe Makito, Inoue Ryuji, Yanase Toshihiko and Kawanami Daiji. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. : Endocrine journal. 20201119.